SCHEMBL19554196

SCHEMBL19554196

NC(=O)c1ccc2cc(Cl)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.62
PARP1 P09874 1/20 0.59
PLAU P00749 5/20 0.52
ROCK2 O75116 1/20 0.50
PIM1 P11309 1/20 0.50
PIM3 Q86V86 1/20 0.50
KDM4E B2RXH2 1/20 0.49
MAP4K4 O95819 2/20 0.47
CYP2A6 P11509 1/20 0.46
CHEK2 O96017 3/20 0.45
F2 P00734 1/20 0.44
PLG P00747 1/20 0.44
KLKB1 P03952 1/20 0.44
PRSS1 P07477 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
THRB P10828 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PARP15 Q460N3 1/20 0.43
PARP14 Q460N5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27033525 0.94 LCK (0.60) LCKPARP1PLAUROCK2PIM1
SCHEMBL29174256 0.87 LCK (0.53) LCKPARP1PLAUROCK2PIM1
SCHEMBL2363489 0.87 LCK (0.78) LCKPARP1PLAUKDM4EF2
SCHEMBL16585023 0.84 CES2 (0.48) LCKPARP1PLAUKDM4ECYP2A6
SCHEMBL743388 0.81 TSHR (0.60) KDM4ECYP2A6CHEK2KMT2AMEN1
SCHEMBL7608517 0.81 CYP2A6 (0.48) LCKPLAUKDM4ECYP2A6KMT2A
SCHEMBL9318541 0.81 TP53 (0.50) LCKPARP1PLAUROCK2PIM1
SCHEMBL4405181 0.80 LCK (0.75) LCKPARP1PLAUKDM4ECYP2A6
SCHEMBL30935786 0.80 LCK (0.75) LCKPARP1PLAUKDM4ECYP2A6
SCHEMBL11662765 0.79 CYP2A6 (0.55) CYP2A6KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2017192304-A1 ARYLCARBOXAMIDES AND USES THEREOF INCEPTION 1, INC. (US) 2017-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT LCK 1891/4885PARP1 3485/4885PLAU 1022/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT LCK 1891/4885PARP1 3485/4885PLAU 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.